The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Four-Year Data on New Drug for Early AD Positive
Source: Dr. Ram Selvaraju (04/09/2025)

Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.

Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Source: Jason Kolbert (04/09/2025)

These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.

New Drug for Early AD Shown to be Efficacious, Safe
Source: Jason Kolbert (04/09/2025)

Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report.

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal
Source: Streetwise Reports (04/08/2025)

Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential.